Our team2019-02-14T11:18:10+01:00

| Why Analytica Laser?

As a global leader in population health intelligence, we’re committed to providing the highest level of scientific evidence on the real-world value of medicines and health technologies. Every day our work directly benefits millions of patients in advancing access to new therapies that are safer, more convenient and more affordable.

Analytica Laser is part of Certara, the global leader in model-informed drug development and regulatory science. Our joint mission is to change the game in drug development, value assessment and patient access, providing healthcare leaders with unparalleled end-to-end strategy and cutting-edge technology to define, capture, and communicate value —from R&D intelligence all the way to patient care.

analytica-laser

| Why Analytica Laser?

As a global leader in population health intelligence, we’re committed to providing the highest level of scientific evidence on the real-world value of medicines and health technologies. Every day our work directly benefits millions of patients in advancing access to new therapies that are safer, more convenient and more affordable.

Analytica Laser is part of Certara, the global leader in model-informed drug development and regulatory science. Our joint mission is to change the game in drug development, value assessment and patient access, providing healthcare leaders with unparalleled end-to-end strategy and cutting-edge technology to define, capture, and communicate value —from R&D intelligence all the way to patient care.

analytica-laser

Expert Leadership

IWe’re powered by a renowned, multi-national scientific staff with regional experts across all key markets. Analytica Laser’s experienced team unites 100+ specialists and consultant, most with advanced degrees. As a member of Certara, the global leader in model-informed drug development and regulatory science, we are part of a global staff of 700+ professionals across 30+ offices around the world. More about the Senior Analytica Laser team below.

EXECUTIVE MANAGEMENT

Roman Casciano

General Manager of Analytica Laser &
SVP, Market Access, HEOR and Real-world Evidence, Certara

BIO

Since 1997, Analytica Laser has been committed to providing the highest quality evidence and insights on the value of medicines and health technologies. As a member of the Certara family, our global teams are driving impactful science every day – from R&D intelligence all the way to patient access.

EXECUTIVE MANAGEMENT

Roman Casciano

General Manager of Analytica Laser &
SVP, Market Access, HEOR and Real-world Evidence, Certara

Since 1997, Analytica Laser has been committed to providing the highest quality evidence and insights on the value of medicines and health technologies. As a member of the Certara family, our global teams are driving impactful science every day – from R&D intelligence all the way to patient access.

Analytica Laser and Certara created the industry’s leading team of 250+ modeling and analytical scientists, integrating HEOR and real-world value assessments with pharmacometrics data, providing unique insights on safety, efficacy and effectiveness. For our customers, this is a unique market advantage.

Billy Amzal

Senior Vice President, Decision and Real-World Data Analytics, Certara

BIO

Billy Amzal

Senior Vice President, Decision and
Real-World Data Analytics, Certara

Analytica Laser and Certara created the industry’s leading team of 250+ modeling and analytical scientists, integrating HEOR and real-world value assessments with pharmacometrics data, providing unique insights on safety, efficacy and effectiveness. For our customers, this is a unique market advantage.

Oliver Leatham

Global Vice President
Value & Access

BIO

Our consultants at Certara Evidence & Access are globally recognized for their work at the new frontier of value assessment and evidence generation, such as informing HTA guidelines, defining value frameworks or specializing in innovative contracting for fast tracked medicines.

Oliver Leatham

Global Vice President
Value & Access

Our consultants at Certara Evidence & Access are globally recognized for their work at the new frontier of value assessment and evidence generation, such as informing HTA guidelines, defining value frameworks or specializing in innovative contracting for fast tracked medicines.

SENIOR GLOBAL TEAM

Lucien Abenhaim

MD, PhD
London, UK

+ Sr. Scientific Advisor
+ Analytica Laser Founder
+ Fmr. General Director of Health,
+ France and frm. Member WHO
+ Executive Council
BIO

Sumeet Bakshi

MBBS, MMS, MBA
London, UK

+ VP, Real World Evidence Solutions
+ 17+years’ experience, fmr. Pfizer and J&J
BIO

Matthew Brougham

MSc, DipHeathEcon
Montréal, Canada

+ Sr. Global Consultant
+ Fmr. VP, CADTH (Canada) and Fmr.
+ CEO PHARMAC (NZ)
+ 20+ years’ HTA/HEOR experience
BIO

Patrizia Berto

PharmD, MBA
Milan, Italy

+ Sr. Global Consultant and Managing
+ VP, Italy
+ 30 years’ in biopharma with 20 years’ of
+ HECON/ MA consulting
BIO

Jenifer Ehreth

PhD
Paris, France

+ Sr. Global Consultant
+ 15+ years’ experience in biopharma
+ and devices
+ University Prof. in Health Economics
BIO

Artak Khachatryan

PhD, MD
London, UK

+ Sr. Director, Pharmacoepidemiology
+ 10+ years’ experience as lead
+ epidemiologist in various international
+ studies
BIO

Hanane Khoury

PhD
Montréal, Canada

+ Assoc. Director, MCDA expert and Lead
+ investigator for the EVIDEM
+ collaboration
+ 10+ years’ experience in MCDA and
+ reimbursement dossier development
BIO
anna

Anna Kondic

PhD, MBA
Parsippany, NJ

+ VP, Decision Analytics
+ Lead, Early HEOR and Analytics Services
+ Distinguished Scientist, fmr. Merck
+ and Novartis
+    PhD in Mathematics, Duke University
+ and MBA, NYU Stern School of Business
BIO
analytica-laser

Johanna Lister

MSc
Lörrach, Germany

+ Senior Director, Decision Analytics
+ Global Head of Health Economic
+ Modelling
+ 15+ years of experience in health
+ analytics
BIO
analytica laser

Marta Martinez

MS, PharmD
Madrid, Spain

+ Director, of Clinical Operations for
+ Outcomes Research
+ Implementing, conducting and managing
+ international Post-Authorizations,
+ Observational and Late Phase Studies
+ 10+ years of experience
+
BIO

Michael Minshall

MPH
New York, USA

+ Sr Consultant HEOR
+ 11+ year’s Global HEOR Experience
BIO

Elvira Müller

PhD, MPH
Lörrach, Germany

+ Managing VP, Germany
+ 15+years‘ experience in HTA and global
+ market access
BIO
analytica_laser

Kurt Neeser

PhD, MPH
Lörrach, Germany

+ Senior Director, HEOR
+ Health Economics, Modelling and
+ Literature Review
+ 20+ years of experience
+
BIO

Ulrich Neumann

MSc, MA, FRSA
New York, USA

+ Sr. Director & Head, US Value & Access
+ Business Consultant, Commercial
+ Strategy
+ 12+ years’ in Product Dev.& Marketing
BIO
analytica-laser

Lee Stern

MSc
New York, USA

+ VP, Business Development
+ 15+ years’ experience in HEOR
+ and global market access client
+ engagements
BIO

Dima Samaha

PharmD, MAS
London, UK

+ Senior Director, Value Strategy &
+ Payer Insights
+ Fmr. Advisor on Innovation and External
+ Affairs at INESSS, Québec
BIO
analytica-laser

Elvira Schmidt

MS
Lörrach, Germany

+ Senior Director, Value & Access
+ Dossiers & Submissions, HTA, Market
+ Access
+ 15+ years of experience
+
BIO

Jacek Walczak

MD Spec
Krakow, Poland

+ VP, Central and Eastern Europe
+ 15+ years’ experience global market
+ access and systematic reviews
BIO

Global Presence

With offices across Europe & North America and an unparalleled international network, Analytica Laser is well-positioned to provide strategic consulting and scientific research services to the global health care industry. Our consulting, research and data solutions are currently employed by the leading biopharma and public health innovators in over 20 countries. Together with our colleagues at Certara, our work has unparalleled global reach.

New YorkMontrealLondonMadridParisLorrachMilanKrakow

Recent Research

| Publications by Analytica Laser Staff

Amzal B, Sénécal M, de Jong FA, Mamlouk K, Becker CC. Imputing missing values to estimate health-related quality of life (HR-QOL) in metastatic pancreatic cancer (MPC) treated with 5-fluorouracil and leucovorin, with and without liposomal irinotecan (NAL-IRI). Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Becker CC, Amzal B, de Jong FA, Sénécal M, Mamlouk K. Multivariate analysis of health-related quality of life (HR-QOL) in metastatic pancreatic cancer (MPC) treated with 5- fluorouracil and leucovorin, with and without liposomal irinotecan (NAL-IRI). Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Berto P, Bilato C, Bonora E, De Conto U, Graziani MS, Pauletto P, Vettor R, Zambon A. Cardiovascular risk and increased plasma LDL cholesterol concentration: the role of the Regional Health Service GRHTA 2017; 4(1): e44 – e46

Capkun G, Schmidt J, Ghosh S, Sharma H, De Vera A, Demin I, Risson V, Amzal B, Wiecek W, Obadia T. Evidence-based bayesian modeling to predict survival in patients with sporadic inclusion body myositis (SIBM). Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Castejón N, Cappelleri JC, Cuervo J, Lang K, Mehta P, Mokgokong R, Mamolo C. Estimating health state utilities for patients with acute myeloid leukemia. Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Cui YA, Patel H, O’Neil WM, Li S, Saddier P. Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world. Hum Vaccin Immunother. 2017;13(6):1-13.

Ehreth J, Mueller E, Neeser K. New European medical device directive and the potential consequences for us and European manufacturers. Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Goetghebeur M, Samaha D, O’Neil WM, Khoury H, Bennetts L, Lavoie L, Wagner M, Badgley D, Gabriel S, Berthon A, Dolan J, Kulke M. MCDA to explore GEP-NET decision criteria with patients and clinicians. Poster presented at HTAi 2017 Annual Meeting; 2017 Jun 17-21.; Rome, Italy.

Goetghebeur M, Samaha D, Khoury H, O’Neil WM, Lavoie L, Bennetts L, Wagner M, Badgley D, Gabriel S, Berthon A, Dolan J, Kulke M. Reflective MCDA to identify decision drivers for patients with GEP-NET. Poster presented at HTAi 2017 Annual Meeting; 2017 Jun 17-21.; Rome, Italy.

Jalbert J. Use of multiple sources of electronic healthcare record (EHR) drug data to study somatostatin analogue (SSA) dosing for gastroenteropancreatic neuroendocrine tumor (GEP-NET) treatment. Poster presented at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management; 2017 Aug 26-30.; Montreal, Canada.

Jalbert J. An algorithm to identify somatostatin analogue (SSA) dose escalations. Poster presented at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management; 2017 Aug 26-30.; Montreal, Canada.

Jalbert JJ, Casciano R, Meng J, Dutton T, Brais LK, Pulgar SJ, Berthon A, Gabriel S, Dinet J, Kulke M. Somatostatin analog (SSA) dose escalations among patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET) treated at a tertiary referral center. Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Karcher H, Wiecek W, Casciano R, Amzal B. Estimating the impact of channeling bias on real-world survival in advanced cancer. Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Karcher H, Fu S, Zöllner Ankarfeldt M, Haro J, Nordon C. Optimal design of pre-authorization trials for effectiveness evaluation in schizophrenia. Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Karcher H, Wiecek W, Gultyaev D, Casciano R, Amzal B. HOPE, “Health Outcomes Performance Estimator”: A new tool to predict real-life outcomes. Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Lavoie L, O’Neil B. Evolution of the market for integrase inhibitors for HIV infection among adult patients in Canada. Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Lavoie L, O’Neil B. Understanding the Classes: Drugs for Partial-Onset Seizures in Epilepsy. Provincial Reimbursement Advisor. 2017;20(2):49-60.

Meng J, Casciano R, Lee YC, Stern L, Gultyaev D, Tong L, et al.  Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population. J Manag Care Spec Pharm. 2017;23(4):446-52.

Meyer F, Petrie C, Samaha D, Houyez F, Fitzpatrick Z. The value of a cure: is HTA ready for breakthroughs? Panel presented at HTAi 2017 Annual Meeting; 2017 Jun 17-21.; Rome, Italy.

Neeser K, Mueller E, Ehreth J. Medical devices under the new European rule: risks and opportunities. Poster presented at HTAi 2017 Annual Meeting; 2017 Jun 17-21.; Rome, Italy.

Nordon C, Bovagnet T, Belger M, Jimenez J, Olivares R, Chevrou-Severac H, et al.  Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: A case study using the SOHO database. Schizophr Res. 2017;

Pariti B. Analysis of treatment costs of malaria in a tertiary care hospital: an Indian perspective. Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Rüther A, Hebborn A, Spurrier-Bernard G, Facey K, Müller E. Joint HTA assessment: is it worth the effort? An outlook to 2020 and beyond from various perspective. Panel presented at HTAi 2017 Annual Meeting; 2017 Jun 17-21.; Rome, Italy.

Wagner M, Khoury H, Bennetts L, Berto P, Ehreth J, Badia X, et al.  Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA. BMC Cancer. 2017;17:272.

Wiecek W, Amzal B, Casciano R, Karcher H. Estimating the impact of channeling bias on real-world survival in advanced cancer. Poster presented at the ISPOR 22nd Annual International Meeting; 2017 May 20-24.; Boston, MA.

Nordon C, Karcher H, Groenwold RH, Ankarfeldt MZ, Pichler F, Chevrou-Severac H, Rossignol M, Abbe A, Abenhaim L; GetReal consortium. The “Efficacy-Effectiveness Gap”: Historical Background and Current Conceptualization. Value Health. 2016 Jan;19(1):75-81.
Grimaldi-Bensouda L, Klungel O, Kurz X, de Groot MCH, Afonso A, de Bruin M, Reynolds R, Rossignol M. Calcium channel blockers and cancer risk: an analysis using the UK Clinical Practice Research Datalink (CPRD). BMJ Open. 2016 Jan 8;6(1):e009147.

Lavoie L, Khoury H, Welner S, and Briere J.B. Burden and prevention of adverse cardiac events in patients with concomitant chronic heart failure and coronary artery disease: a literature review. Cardiovasc Ther. 2016.

Wagner M, Khoury H, Willet J, Rindress D, and Goetghebeur M. Can the EVIDEM framework tackle issues raised by evaluating treatments for rare diseases: analysis of issues and policies, and contextspecific adaptation. Pharmacoeconomics, 2016 34(3): 285-301.

Khoury H, Lavoie L, Welner S, and Folkerts K. Disease burden and unmet needs for the prevention of major adverse cardiac events in patients with coronary or peripheral arterial disease. Cardiovasc Ther. 2016.

Patel H, Khoury H, Girgenti D, Welner S, and Yu H. Burden of Surgical Site Infections Associated with Arthroplasty and the Contribution of Staphylococcus aureus. Surg Infect (Larchmt.) 2016 17 (1):78-88.

Aiassa E, Amzal B, Deeks J, Frampton G, Glanville J, Greiner M, Higgins J, et al. Applicability and feasibility of systematic review for performing evidence-based risk assessment in food and feed safety. Crit Rev Food Sci Nutr. 2015;55(7):1026-34.
Sripan P, Amzal B. et al. Modeling the effect of antiretroviral therapy on in-utero and intra-partum
mother-to-child transmission of HIV. PLOS One. 2015 May 19;10(5):e0126647.

Grimaldi-Bensouda L, Abenhaim L, Massol J, Guillemot D, Avouac B, Duru G, Lert F, Magnier AM, Rossignol M, Rouillon F, Begaud B; EPI3-LA-SER Group. Utilization of psychotropic drugs by patients consulting for sleeping disorders in homeopathic and conventional primary care settings: the EPI3 cohort study. Homeopathy. 2015 Jul;104(3):170-5.

Grimaldi-Bensouda L, Alpérovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, Richette P; PGRx MI Group. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015 May;74(5):836-42.

Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Jaff MR, White CJ, Rothman AT, et al. Outcomes after carotid artery stenting in Medicare beneficiaries, 2005 to 2009. JAMA Neurol. 2015; 72(3):276-86.

Kumamaru H, Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Williams LA, Chen CY, et al. Surgeon case volume and 30-day mortality after carotid endarterectomy among contemporary medicare beneficiaries: before and after national coverage determination for carotid artery stenting. Stroke.
2015; 46(5):1288-94.

Paul S, Isaacs AJ, Jalbert J, Osakwe NC, Salemi A, Girardi LN, et al. A population-based analysis of robotic-assisted mitral valve repair. Ann Thorac Surg. 2015; 99(5):1546-53.

Perrin A, Sherman S, Pal S, Chua A, Gorritz M, Liu Z, et al. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. J Med Econ. 2015; 18(3):200-9.

Sherman S, Amzal B, Calvo E, Wang X, Park J, Liu Z, et al. An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed. Clin Ther. 2015; 37(11): 2552–2559.

Szkultecka-Dębek M, Walczak J, Augustyńska J, Miernik K, Stelmachowski J, Pieniążek I, Obrzut G, Pogroszewska A, Paulić G, Marić D, Antolić S, Tavcar R, Indrikson A, Aadamsoo K, Jankovic S, Pulay A, Rimay J, Varga M, Sulkova I, Veržun P. Epidemiology and Treatment Guidelines of Negative
Symptoms in Schizophrenia in Central and Eastern Europe: A Literature Review, Clinical Practice & Epidemiology in Mental Health. Clin Pract Epidemiol Ment Health. 2015; 11:158-165.

Szkultecka-Dębek M, Walczak J, Augustyńska J, Miernik K, Stelmachowski J, Pieniążek I, Obrzut G, Pogroszewska A, Paulić G, Marić D, Antolić S, Pecenak J, Tavcar R, Indrikson A, Aadamsoo K, Jankovic S, Pulay A, Rimay J, Varga M, Sulkova I, Veržun P. Assessment of quality of life in patients with schizophrenia and their caregivers in selected Central and Eastern European countries: A literature
review. JHPOR. 2015; 1: 76-92.

Bennetts L, Wagner M, Guiliano A, Palefsky J, Steben M, and Weiss T. Associations of anogenital lowrisk human papillomavirus infection with cancer and acquisition of HIV. Sex Transm Dis. 2015 Oct;42(10):541-4.

Wagner M, Bennetts L, Patel H, Welner S, de Sanjose S, and Weiss T.W. Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females. Infect Agent.Cancer. 2015; 10 (13):1-6.

Wahlster P, Goetghebeur M, Kriza C, Niederländer C, Kolominsky-Rabas P. Balancing costs and benefits at different stages of medical innovation: a systematic review of multi-criteria decision analysis (MCDA). BMC Health Serv Res. 2015; 15:262.

Wahlster P, Goetghebeur M, Schaller S, Kriza C, Kolominsky-Rabas P. Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study. Health Res Policy Syst. 2015; 13(1):24.

Berto P, Adami S, Botsios C, Fantelli V, Grion AM, Ometto F, Punzi L, Roni C, Scroccaro G. Real world data use and applications in the integrated management of rheumatic disease. GRHTA. 2015; 2(3): 152–157.

Mannucci E, Torre E, Berto P. Dapagliflozin as add-on to metformin; network meta-analysis and budget impact analysis. GRHTA. 2015; 2(3): 125-134 .

Perrin A, Sherman S, Pal S, et al. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. J Med Econ. 2015 Mar; 18(3):200-9.

López MF, Mingot ME, Valcárcel D, et al. Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain. Med Clin (Barc). 2015 May 8 ;144(9): 389-96.

Paul S, Isaacs AJ, Jalbert J, Altorki NK, Isom OW, Sedrakyan A. Safety of Robotic-Assisted Mitral Valve Repair: Analysis of National Data. Ann Thorac Surg. 2015; 99(5):1546-1553.

Kumamaru H, Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Williams LA, Chen CY, Seeger JD, Liu J, Franklin JM, Setoguchi S. Surgeon Case Volume and 30-day Mortality after Carotid Endarterectomy among Contemporary Medicare Beneficiaries: Before and After National Coverage Decision for
Carotid Artery Stenting. Stroke. 2015; 46(5):1288-1294.

Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Jaff MR, White CJ, Rothman AT, Seeger JD, Kumamaru H, Williams LA, Chen CY, Liu J, Tsai TT, Aronow HD, Johnston JA, Brott, TG, Setoguchi S. Outcomes After Carotid Artery Stenting in Medicare Beneficiaries, 2005-2009. JAMA Neurol 2015; 72(3):276-86.

Wagner M, Bennetts L, Patel H, Welner S, de Sanjose S, Weiss TW. Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females. Infect Agent Cancer. 2015 Apr 28;10:13.

Chang CL, Schabert VF, Munakata J, Donga P, Abhyankar S, Reyes CM, Yim YM. Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Res. 2015 Aug;25(4):312-20.

Walzer S, Chouaid C, Lister J, Gultyaev D, Vergnenegre A, de Marinis F, et al. Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. Expert Rev Anticancer Ther. 2015; 15(1):121-8.

Aiassa E, Amzal B, Deeks J, Frampton G, Glanville J, Greiner M, Higgins J, et al. Applicability and feasibility of systematic review for performing evidence-based risk assessment in food and feed safety. Crit Rev Food Sci Nutr. 2015; 55(7):1026-34.

Sripan P, Amzal B. et al. Modeling the effect of antiretroviral therapy on in-utero and intra-partum mother-to-child transmission of HIV. PLoS One. 2015 May 19;10(5):e0126647.

Fu, S., Celeux, G., Bousquet, N. and Couplet, M. Bayesian inference for inverse problems occurring in uncertainty analysis. Int J Uncertain Quantif. 2015; 5(1): 73–98.

Fu, S. Hierarchical Bayesian LASSO for a negative binomial regression. J Stat Comput Simul. 2015.

Castejón N, Khalaf K, Ni Q, Cuervo J, Patrick DL. Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials. Health Qual Life Outcomes. 2015 Aug 1;13:116.

Grimaldi-Bensouda L, Alperovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, Richette P. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2014 Jan 6.
Grimaldi-Bensouda L, Cameron D, Marty M, Barnett AH, Penault-Llorca F, Pollak M, Charbonnel B, Riddle M, Mignot L, Boivin JF, Khachatryan A, Rossignol M, Benichou J, Alperovitch A, Abenhaim L. Risk of breast cancer by individual insulin use: an international multicenter study. Diabetes Care. 2014 Jan; 37(1):134-43.

Lert F, Grimaldi-Bensouda L, Rouillon F, Massol J, Guillemot D, Avouac B, Duru G, Magnier AM, Rossignol M, Abenhaim L, Begaud B. Characteristics of patients consulting their regular primary care physician according to their prescribing preferences for homeopathy and complementary medicine. Homeopathy. 2014 Jan; 103(1):51-7.

Viele K, Berry S, Neuenschwander B, Amzal B, Chen F, Enas N, Hobbs B, Ibrahim JG, Kinnersley N, Lindborg S, Micallef S, Roychoudhury S, Thompson L. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014 Jan; 13(1):41-54.

Stålhammar J, Stern L, Linder R, Sherman S, Parikh R, Ariely R, Deschaseaux C, Wikström G. The burden of preserved ejection fraction heart failure in a real-world Swedish patient population. J Med Econ. 2014 Jan; 17(1):43-51.

Nordon C, Falissard B, Gerard S, Angst J, Azorin JM, Luquiens A, Reed C, Lukasiewicz M, Gasquet I. Patient satisfaction with psychotropic drugs: Validation of the PAtient SAtisfaction with Psychotropic (PASAP) scale in patients with bipolar disorder. Eur Psychiatry. 2014 Mar; 29(3):183-90.

Nordon C, Rouillon F, Azorin JM, Barry C, Urbach M, Falissard B. Trajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up study. Acta Psychiatr Scand. 2014 Feb; 129(2):116-25.

Abbing-Karahagopian V, Kurz X, de Vries F, van Staa TP, Alvarez Y, Hesse U, Hasford J, van Dijk L, de Abajo FJ, Weil JG, Grimaldi-Bensouda L, Egberts AC, Reynolds RF, Klungel OH. Bridging Differences in Outcomes of Pharmacoepidemiological Studies: Design and First Results of the Protect Project. Curr Clin Pharmacol. 2013 Nov 11;
Grimaldi-Bensouda L, Aubrun E, Leighton P, Benichou J, Rossignol M, Abenhaim L.Agreement between patients’ self-report and medical records for vaccination: the PGRx database. Pharmacoepidemiol Drug Saf. 2013 Mar; 22(3):278-85.

Grimaldi-Bensouda L, Guillemot D, Godeau B, Benichou J, Lebrun-Frenay C, Papeix C, Labauge P, Berquin P, Penfornis A, Benhamou PY, Nicolino M, Simon A, Viallard JF, Costedoat-Chalumeau N, Courcoux MF, Pondarre C, Hilliquin P, Chatelus E, Foltz V, Guillaume S, Rossignol M, Abenhaim L.Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2013 Nov 8;

Grimaldi-Bensouda L, Rossignol M, Aubrun E, Benichou J, Abenhaim L. Reply to: Comments on Agreement between patients’ self-report and physicians’ prescriptions on non-steroidal anti-inflammatory drugs and other drugs used in musculoskeletal disorders’. Pharmacoepidemiol Drug Saf. 2013 Jun; 22(6):668-9.

Grimaldi-Bensouda L, Rossignol M, Danchin N, Dallongeville J, Bruckert E, Banayan J, Cottin Y, Aubrun E, Khachatryan A, Benichou J, Abenhaim L.Real-life effectiveness of statins in the prevention of first acute coronary syndrome in France: a prospective observational study. Int J Cardiol. 2013 Nov 15; 169(4):271-5.

Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, Molimard M, Abenhaim L. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013 Feb 1; 143(2):398-405.

Grimaldi L, Danzi M, Reggio S, Pannullo M, Danzi R, Lauria R.Decision making in borderline ovarian tumors: report of a rare case of mesosigma psammocarcinoma. Ann Ital Chir. 2013 Sep 3; 84(ePub)

Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med 2013;23(1):55-60.

Tanios N, Wagner M, Tony M, Baltussen R, van TJ, Rindress D, et al. Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers. Int J Technol Assess Health Care 2013;29(4):456-65.

O’Neil WM, Welner SA, Lip GY. Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions? Thromb Haemost 2013;109(3)

Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013;13:39

Casciano R, Wang X, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Strosberg J, Cadiot G, Riechelmann R.International practice patterns and resource utilization in the treatment of neuroendocrine tumors. Pancreas. 2013 Mar; 42(2):339-47.

Han T, Rong G, Quan D, Shu Y, Liang Z, She N, Liu M, Yang B, Cheng G, Lv Y, Stern L. Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. Biomed Res Int. 2013; 2013:320560.

Hofstetter S, Stern L, Willet J.Key issues in addressing the clinical and humanistic burden of short bowel syndrome in the US. Curr Med Res Opin. 2013 May; 29(5):495-504.

Kobashigawa LC, Hamilton M, Rafiei M, Stern L, Bairey Merz CN.Hormone therapy in women after heart transplantation. Transplant Proc. 2013 Nov; 45(9):3386-8.

Patel A, Roston A, Tilmon S, Stern L, Roston A, Patel D, Keith L. Assessing the extent of provision of comprehensive medical care management for female sexual assault patients in US hospital emergency departments. Int J Gynaecol Obstet. 2013 Oct; 123(1):24-8.

Strosberg J, Casciano R, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Wang X, Grzegorzewski KJ.United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment. World J Gastroenterol. 2013 Apr 21; 19(15):2348-54.

Thompson KM, Stern L, Gelt M, Speidel JJ, Harper CC.Counseling for IUDs and implants: are health educators and clinicians on the same page? Perspect Sex Reprod Health. 2013 Dec; 45(4):191-5.

Agüera Ortiz L, Montón C, Cuervo J, Medina E, Diaz-Cuervo H, Maurino J.Adaptation into Spanish of the Clinically Useful Depression Outcome Scale (CUDOS) for assessing major depressive disorder from the patient’s perspective. Actas Esp Psiquiatr. 2013 Sep-Oct; 41(5):287-300.

Catalan P, Callejo D, Blasco JA. Cost-effectiveness analysis of 64-slice computed tomography vs. cardiac catheterization to rule out coronary artery disease before non-coronary cardiovascular surgery. Eur Heart J Cardiovasc Imaging. 2013 Feb; 14(2):149-57.

Castro-Diaz D, Callejo D, Cortes X, Perez M. Study of Quality of life in Patients with Benign Prostatic Hyperplasia under Treatment with Silodosin. Actas Urol Esp. 2013 Nov 22;

Jelsma JG, van Poppel MN, Galjaard S, Desoye G, Corcoy R, Devlieger R, van Assche A, Timmerman D, Jans G, Harreiter J, Kautzky-Willer A, Damm P, Mathiesen ER, Jensen DM, Andersen L, Dunne F, Lapolla A, Di Cianni G, Bertolotto A, Wender-Oegowska E, Zawiejska A, Blumska K, Hill D, Rebollo P, Snoek FJ, Simmons D. DALI: Vitamin D and lifestyle intervention for gestational diabetes mellitus (GDM) prevention: an European multicentre, randomised trial – study protocol. BMC Pregnancy Childbirth. 2013 Jul 5; 13:142.

Julián-Mauro JC, Cuervo J, Rebollo P, Callejo D. Employment status and indirect costs in patients with renal failure: differences between different modalities of renal replacement therapy. Nefrologia. 2013; 33(3):333-41.

Jimenez-Cidre MA, Lopez-Fando L, Esteban-Fuertes M, Prieto-Chaparro L, Llorens-Martinez FJ, Salinas-Casado J, Castro-Diaz D, Muller-Arteaga C, Adot-Zurbano JM, Rodriguez-Escobar F, Gutierrez C, Arlandis-Guzman S, Bonillo-Garcia MA, Madurga-Patuel B, Leva-Vallejo M, Franco de Castro A, Peri-Cusi L, Conejero-Sugranes J, Jimenez-Calvo J, Rebollo P, Mora A. The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women. Neurourol Urodyn. 2013 Nov 22;

Karcher H, Dinet J, Amzal B, Marteau F, Obrzut G, Pieniazek I, Brulais S, Gabriel S, Prototype Model in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): A Tool to Position New Treatments in the Patient Pathway? Value in Health 2013; 16(7):A593

Meads C, Auguste P, Davenport C, Malysiak S, Sundar S, Kowalska M. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modeling, HTA, 2013;17(12):1-323

Meads C, Sutton A, Małysiak S, Kowalska M, Zapalska A, Rogozinska E, Baldwin P, Rosenthal A, Ganesan R, Borowiack E, Barnton P, Roberts T, Sundar S, Khan K. Sentinel lymph node status in vulval cancer: systematic reviews of test accuracy and decision-analytic model-based economic evaluation; Health Technol Assess. 2013;17(60):1-216

Roos C, Borowiack E, Kowalska M, Zapalska A, Mol B, Mignini L, Meads C, Walczak J, Khan K; the EBM CONNECT collaboration. What do we know about tocolytic effectiveness and how do we use this information in guidelines? A comparison of evidence grading; BJOG. 2013 Sep 10

Walczak J, Lipińska M, Jarosz J, Moczyński W, Ślązak B, Laczewski T, Clinical Effectiveness Analysis of Deferasirox for the Treatment of Iron Overload Due to Frequent Blood Transfusions; Value in Health 2013;16(7): A377-A378

Walczak J, Obrzut G, Sołtys E, Laczewski T, The Budget Impact Analysis of Deferasirox for the Treatment of Iron Overload Due to Frequent Blood Transfusions in Children and Adolescents (Age ≤18 Years), Value in Health 2013, 2013; 16( 7): A379

Walczak J, Stelmachowski J, Obrzut G, Hubert A, Cost-Effectiveness Analysis of Cysteamine in the Treatment of Patients with Cystinosis – a Rare Disease; Value in Health 2013; 16(7):A383

Walczak J, Sołtys E, Obrzut G, Laczewski T, Cost-Utility Analysis of Deferasirox for the Treatment of Iron Overload Due to Frequent Blood Transfusions in the Children and Adolescents, Value in Health 2013; 16(7): A385

Walczak J, Kopel J, Sołtys E, Dziurda D, Cost-Utility Analysis (CUA) of Belimumab (BEL) in the Treatment of Adult Patients with Active, Autoantibody-Positive Systemic Lupus Erythematosus (SLE), Value in Health 2013; 16(7): A385

Walczak J, Augustyńska J, Miernik K, Stelmachowski J, Pieniazek I, Obrzut G, Pogroszewska A, Szkultecka-Debek M, Paulic G, Maric D, Sinisa A, Pecenak J, Tavcar R, Indrikson A, Jankovic S, Pulay AJ, Rimay J, Varga M, Sulkova I; Schizophrenia and Negative Symptoms – Burden of the Disease in Seven Central and Eastern European (CEE) Countries: THE Results of the Literature Review; Value in Health 2013, Vol. 16, Issue 7, Pages A545-A546

Bakhai A, Sandberg A, Mittendorf T, Greiner W, Oberdiek AM, Berto P, Franczok E, Lobban T, Zamorano JL. Patient perspective on the management of atrial fibrillation in five European countries. BMC Cardiovasc Disord. 2013 Dec 1;13(1):108.

Pierelli L, Berto P, Accorsi P, Milone G, Lopatriello S, Aiello A, Iacopino P, Olivieri A, Rambaldi A, Bosi A. The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: Results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey. Transfus Apher Sci. 2013 Dec;49(3):615-22.

Cortesi PA, Mencacci C, Luigi F, Pirfo E, Berto P, Sturkenboom MC, Lopes FL, Giustra MG, Mantovani LG, Scalone L.Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study.BMC Psychiatry. 2013 Mar 22;13(1):98.

Quignot N, Bois FY.A computational model to predict rat ovarian steroid secretion from in vitro experiments with endocrine disruptors. PLoS One. 2013; 8(1):e53891.

Gorse P, Nordon C, Rouillon F, Pham-Scottez A, Revah-Levy A.Subjective motives for requesting in-patient treatment in female with anorexia nervosa: a qualitative study. PLoS One. 2013; 8(10):e77757.

Chen CY, Stevenson LW, Stewart GC, Seeger JD, Williams L, Jalbert JJ, Setoguchi S.Impact of baseline heart failure burden on post-implantable cardioverter-defibrillator mortality among medicare beneficiaries. J Am Coll Cardiol. 2013 May 28; 61(21):2142-50.

Andersen M, Bergman U, Choi NK, Gerhard T, Huang C, Jalbert J, Kimura M, Kimura T, Kubota K, Lai EC, Ooba N, Park BJ, Pratt N, Roughead EE, Sato T, Setoguchi S, Shin JY, Sundström A, Yang YH. The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia. Pharmacoepidemiol Drug Saf. 2013 Jul; 22(7):700-4.

Dionne CE, Bourbonnais R, Fremont P, Rossignol M, Stock SR, Laperriere E. Obstacles to and facilitators of return to work after work-disabling back pain: the workers’ perspective. J Occup Rehabil. 2013 Jun; 23(2):280-9.

Grimaldi-Bensouda L et al. Does risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res. 2012 Feb; 134(2-3):187-94.
Rossignol M, Begaud B, Engel P, Avouac B, Lert F, Rouillon F, Benichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L.Impact of physician preferences for homeopathic or conventional medicines on patients with musculoskeletal disorders: results from the EPI3-MSD cohort. Pharmacoepidemiol Drug Saf. 2012 Oct; 21(10):1093-101.

Dorne JL, Amzal B, Bois F, Crepet A, Tressou J, Verger P. Population effects and variability. Methods Mol Biol. 2012; 929:521-81.

Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): Applying the EVIDEM framework to medicines appraisal. Med Decis Making 2012;32(2):376-88.

Ogilvie I, Khoury H, Goetghebeur MM, Giaquinto C. Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis 2012;12(1):62

Hackshaw MD, Krishna A, Mauro DJ. Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery. Clinicoecon Outcomes Res 2012;4:169-76.

Howidi M, Al Kaabi N, El Khoury A, Brandtmüller A, Nagy L, Richer E, et al. Burden of acute gastroenteritis among children younger than 5 years of age – a survey among parents in the United Arab Emirates. BMC Pediatr 2012;12(1):74

Ma L, White R, Narayanan S, Schmader MD. Economic burden of herpes zoster among skilled nursing facility residents in the US. J Am Med Dir Assoc 2012;13(1):54-9.

Yan S, Colin X, Coudray-Omnes C, Guido-Morin P, Kommala DR. A budget impact analysis comparing a Hydrofiber(R) dressing to an alginate dressing in managing exuding venous leg ulcers in France. Int Wound J 2012;

Casciano R, Wang X, Stern L, Parikh R, Chulikavit M, Willet J, et al. International practice patterns and resource utilization in the treatment of neuroendocrine tumors. Pancreas [in press]. 2012;

Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial. J Hosp Med. 2012;7(3):176-82.

Buckley BS, Harreiter J, Damm P, Corcoy R, Chico A, Simmons D, et al. Gestational diabetes mellitus in Europe: prevalence, current screening practice and barriers to screening. A review. Diabet Med. 2012;29(7):844-54.

Espuna-Pons M, Castro-Diaz D, Diaz-Cuervo H, Perez M. Impact of Overactive Bladder Treatment on Associated Comorbidities. Actas Urol Esp. 2012;

Ortega F, Otero A, Crespo JF, Delgado JF, Borro JM, Cuervo J, et al. Satisfaction and adherence with immunosuppressant treatment in renal transplant patients living with a working graft. J Nephrol. 2012;0.

Parra E, Arenas MD, Alonso M, Martinez MF, Gamen A, Balda S, et al. Outcomes weighting for comprehensive haemodialysis centre assessment. Nefrologia. 2012;32(5):659-63.

Torrelo A, Ortiz J, Alomar A, Ros S, Prieto M, Cuervo J. Atopic dermatitis: impact on quality of life and patients’ attitudes toward its management. Eur J Dermatol. 2012;22(1):97-105.

Villa G, Fernandez-Ortiz L, Cuervo J, Rebollo P, Selgas R, Gonzalez T, et al. Cost-effectiveness analysis of the Spanish renal replacement therapy program. Perit Dial Int. 2012;32(2):192-9.

Villa G, Sanchez-Alvarez E, Cuervo J, Fernandez-Ortiz L, Rebollo P, Ortega F. Cost-effectiveness analysis of timely dialysis referral after renal transplant failure in Spain. BMC Health Serv Res. 2012;12(1):257

Garbacka M, Zawieja J, Prząda-Machno P, Kroc J, Walczak J, Treatment of well-differentiated pancreatic neuroendocrine tumors with sunitinib in patients with disease progression: Costutility and cost-effectiveness analysis. Value Health. 2012;15(7):A426

Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Roseboom T, Tomlinson JW, et al. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. BMJ. 2012;344:e2088.

Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Duda W, Borowiack E, et al. Interventions to reduce or prevent obesity in pregnant women: a systematic review. Health Technol Assess. 2012;16(31):iii-191.

Walczak J, Józwiak M, Jasinska A, Garbacka M. A cost-effectiveness analysis of programmable baclofen pump therapy in children with spastic cerebral palsy. JHPOR. 2012;104-15.

Walczak J, Miernik K, Kuter I, Ussowicz M. Extracorporeal photopheresis for the treatment of patients with acute or chronic graft versus host disease (GVHD), refractory to corticosteroids-a sytematic review. Value Health. 2012; 15(7): A345-A346

Walczak J, Wepsiec K, Lemanski T, Zawieja J, Ussowicz M. Economical aspects of the reimbursement of extracorporeal photopheresis (ECP) in treatment of patients with graft-versushost disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) who are refractory to steroid treatment. Value Health. 2012;15(7):A349

Walczak J, Garbacka M, Jarosz J, Lipińska M, Zawieja J, Prząda-Machno, Kroc J, Clinical effectiveness and cost-utility analysis of sunitinib for the treatment of pancreatic neuroendocrine tumors, Journal of Health Policy & Outcomes Research, 2012, 2, 48-63

Wilk N, Kloc K, Zieba P. Outcome of price negotiations on reimbursed medicines. Pharma Poland News. 2012;3(72):4-7

Walczak J, Jóźwiak M, Chmiel M, Kowalska M, Assessment of clinical effectiveness of intrathecal baclofen in the treatment of spasticity – systematic literature review (PJRR 1/2012)

Walczak J. Secondary prevention of spontaneous preterm birth. Evidence quality assessment of effectiveness. 2012;

Lee EK, Revil C, Ngoh CA, Lister J, Kwon JM, Park MH, et al. Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea. Clin Ther. 2012;34(6):1408-19.

Lister J, Stanisic S, Kaier K, Hagist C, Gultyaev D, Walzer S. Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain. Clinicoecon Outcomes Res. 2012;4:299-305.

Berto P, Lopatriello S, Aiello A, Corcione F, Melotti G, Spinoglio G, Trapani V. Cost of laparoscopy and laparotomy in the surgical treatment of colorectal cancer. Surgical Endoscopy. Surg Endosc. Surg Endosc. 2012 May;26(5):1444-53.

Pouech C, Tournier M, Quignot N, Kiss A, Wiest L, Lafay F, Flament-Waton MM, Lemazurier E, Cren-Olive C. Multi-residue analysis of free and conjugated hormones and endocrine disruptors in rat testis by QuEChERS-based extraction and LC-MS/MS. Anal Bioanal Chem. 2012 Mar; 402(9):2777-88.

Quignot N, Arnaud M, Robidel F, Lecomte A, Tournier M, Cren-Olive C, Barouki R, Lemazurier E. Characterization of endocrine-disrupting chemicals based on hormonal balance disruption in male and female adult rats. Reprod Toxicol. 2012 Jun; 33(3):339-52

Quignot N, Desmots S, Barouki R, Lemazurier E.A comparison of two human cell lines and two rat gonadal cell primary cultures as in vitro screening tools for aromatase modulation. Toxicol In Vitro. 2012 Feb; 26(1):107-18.

Quignot N, Tournier M, Pouech C, Cren-Olive C, Barouki R, Lemazurier E. Quantification of steroids and endocrine disrupting chemicals in rat ovaries by LC-MS/MS for reproductive toxicology assessment. Anal Bioanal Chem. 2012 Jun; 403(6):1629-40.

Nordon C, Rouillon F, Barry C, Gasquet I, Falissard B.Determinants of treatment satisfaction of schizophrenia patients: results from the ESPASS study. Schizophr Res. 2012 Aug; 139(1-3):211-7.

Pham-Scottez A, Huas C, Perez-Diaz F, Nordon C, Divac S, Dardennes R, Speranza M, Rouillon F.Why do people with eating disorders drop out from inpatient treatment?: the role of personality factors. J Nerv Ment Dis. 2012 Sep; 200(9):807-13.

Dixon A, Khachatryan A, Gilmour S. Does general practice reduce health inequalities? Analysis of quality and outcomes framework data. Eur J Public Health. 2012 Feb; 22(1):9-13.

Dixon A, Khachatryan A, Tian Y.Socioeconomic differences in case finding among general practices in England: analysis of secondary data. J Health Serv Res Policy. 2012 Apr; 17 Suppl 2:18-22.

Barsan C, Zouine M, Maza E, Bian W, Egea I, Rossignol M, Bouyssie D, Pichereaux C, Purgatto E, Bouzayen M, Latche A, Pech JC. Proteomic analysis of chloroplast-to-chromoplast transition in tomato reveals metabolic shifts coupled with disrupted thylakoid biogenesis machinery and elevated energy-production components. Plant Physiol. 2012 Oct; 160(2):708-25.

Bastiat B, Sauviac L, Picheraux C, Rossignol M, Bruand C.Sinorhizobium meliloti sigma factors RpoE1 and RpoE4 are activated in stationary phase in response to sulfite. PLoS One. 2012; 7(11):e50768.

Truchon M, Schmouth MÈ, Côté D, Fillion L, Rossignol M, Durand MJ.Absenteeism screening questionnaire (ASQ): a new tool for predicting long-term absenteeism among workers with low back pain. J Occup Rehabil. 2012 Mar; 22(1):27-50.

Autret-Leca E, Grimaldi-Bensouda L, Daubin C, Poggi P, Collignon AE, Jonville-Bera AP.Heptavalent pneumococcal conjugate vaccine (PCV7): French survey of serious adverse reactions. Therapie. 2011 Jan-Feb; 66(1):81-6.
Grimaldi-Bensouda L, Begaud B, Lert F, Rouillon F, Massol J, Guillemot D, Avouac B, Duru G, Magnier AM, Rossignol M, Abenhaim L.Benchmarking the burden of 100 diseases: results of a nationwide representative survey within general practices. BMJ Open. 2011; 1(2):e000215.

Grimaldi-Bensouda L, Alperovitch A, Besson G, Vial C, Cuisset JM, Papeix C, Lyon-Caen O, Benichou J, Rossignol M.Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. Am J Epidemiol. 2011 Aug 1; 174(3):326-35.

Grimaldi-Bensouda L, Rossignol M, Danchin N, Steg PG, Bessede G, Ovize M, Cottin Y, Autret-Leca E, Benichou J, Abenhaim L.Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs. Heart. 2011 Nov; 97(22):1834-40.

Rossignol M, Begaud B, Avouac B, Lert F, Rouillon F, Benichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L. Who seeks primary care for musculoskeletal disorders (MSDs) with physicians prescribing homeopathic and other complementary medicine? Results from the EPI3-LASER survey in France. BMC Musculoskelet Disord. 2011 Jan 19; 12:21.

Rossignol M, Begaud B, Avouac B, Lert F, Rouillon F, Benichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L. Benchmarking clinical management of spinal and non-spinal disorders using quality of life: results from the EPI3-LASER survey in primary care. Eur Spine J. 2011 Dec; 20(12):2210-6.

Dorne JL, Kass GE, Bordajandi LR, Amzal B, Bertelsen U, Castoldi AF, Heppner C, Eskola M, Fabiansson S, Ferrari P, Scaravelli E, Dogliotti E, Fuerst P, Boobis AR, Verger P. Human risk assessment of heavy metals: principles and applications. Met Ions Life Sci. 2011; 8:27-60.

Julin B, Vahter M, Amzal B, Wolk A, Berglund M, Ekesson A. Relation between dietary cadmium intake and biomarkers of cadmium exposure in premenopausal women accounting for body iron stores. Environ Health. 2011 Dec 16; 10:105.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis. PLoS One. 2011; 6(11):e27427.

Van der Voet H, Perry JN, Amzal B, Paoletti C. A statistical assessment of differences and equivalences between genetically modified and reference plant varieties. BMC Biotechnol. 2011 Feb 16; 11:15.

Khoury H, Ogilvie I, El Khoury A, Yinghui D, Goetghebeur M. Burden of rotavirus gastroenteritis in the Middle Eastern and North African pediatric population. BMC Infect Dis 2011;11(9):1-11.

Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 2011;50(2):401-9.

Khoury H, Welner S, Kubin M, Folkerts K, Haas S. Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show under-utilisation of preventive therapies. Thromb Haemost 2011;106(4):600-8.

Ogilvie I, Welner S, Cowell W, Lip G. Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. Am J Cardiol 2011;108(1):151-61.

Ogilvie I, Welner S, Cowell W, Lip G. Ischemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patients. Thromb Haemost 2011;106(1):34-44.

Ogilvie I, Khoury H, El Khoury A, Goetghebeur M. Burden of rotavirus gastroenteritis in the pediatric population in central and eastern Europe: serotype distribution and burden of illness. Hum Vaccin 2011;7(5):523-33.

Sato R, Milligan G, Molta C, Singh A. Health-related quality of life and healthcare resource use in European patients with plaque psoriasis: an association independent of observed disease severity. Clin Exp Dermatol 2011;36(1):24-8.

Tony M, Wagner M, Khoury H, Rindress D, Papastavros T, Oh P, et al. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Serv Res 2011;11(329):1-13.

Casciano R, Chulikavit M, Di LG, Liu Z, Baladi JF, Wang X, et al. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. Value Health. 2011;14(6):846-51.

Casciano R, Malangone E, Ramachandran A, Gagliardino JJ. A quantitative assessment of patient barriers to insulin. Int J Clin Pract. 2011;65(4):408-14.

Di Lorenzo G, Casciano R, Malangone E, Buonerba C, Sherman S, Willet J, et al. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother. 2011;12(10):1491-7.

Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L. Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL. Clin Appl Thromb Hemost. 2011;17(2):150-

Grau S, Rebollo P, Cuervo J, Gil-Parrado S. [Pharmacoeconomic assessment of daptomycin as first-line therapy for bacteraemia and complicated skin and skin structure infections caused by gram-positive pathogens in Spain]. Rev Esp Quimioter. 2011;24(3):154-63.

Miravitlles M, Llor C, Calvo E, Diaz S, Diaz-Cuervo H, Gonzalez-Rojas N. [Validation of the Spanish version of the Chronic Obstructive Pulmonary Disease-Population Screener (COPD-PS). Its usefulness and that of FEV(1)/FEV(6) for the diagnosis of COPD.]. Med Clin (Barc ). 2011;

Montejo AL, Correas-Lauffer J, Maurino J, Villa G, Rebollo P, Diez T, et al. Estimation of a multiattribute utility function for the Spanish version of the TooL questionnaire. Value Health. 2011;14(4):564-70.

Montejo AL, Lauffer JC, Cuervo J, Rebollo P, Cordero L, Diez T, et al. Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the ‘Tolerability and quality of life’ (TOOL) questionnaire. Ann Gen Psychiatry. 2011;10:6.

Parra Moncasi E, Arenas Jimenez MD, Alonso M, Martinez MF, Gamen PA, Rebollo P, et al. Multicentre study of haemodialysis costs. Nefrologia. 2011;31(3):299-307.

Villa G, Rodriguez-Carmona A, Fernandez-Ortiz L, Cuervo J, Rebollo P, Otero A, et al. Cost analysis of the Spanish renal replacement therapy program. Nephrol Dial Transplant. 2011;26(11):3709-14.

Jarosz J, Miernik K, Wachal M, Walczak J. Clinical effectiveness analysis of naltrexone versus acamprosate and placebo in alcohol dependent patients treated with psychotherapy. Value Health. 2011;14(3):A187-A188

Jarosz J, Miernik K, Wachal M, Walczak J, Krumpl G, Systematic review of the effectiveness of naltrexone vs acamprosate in the treatment of alcohol dependent patients who additionally undergo psychotherapy, HTAi conference, Rio de Janerio 2011

Khan KS, Borowiack E, Roos C, Kowalska M, Zapalska A, Mol BW, et al. Making GRADE accessible: a proposal for graphic display of evidence quality assessments. Evid Based Med. 2011;16(3):65-9.

Walczak J, Semeniuk A, Pacocha K, Nogas G. Budget impact analysis of naltrexone in the treatment of alcohol-dependent patients in Poland. Value Health. 2011;14(3):A188-A189

Walczak J, Gebus E, Pacocha K, Krumpl G, Treatment of alcohol-dependent patients in Poland –is it cost-effective? HTAi conference, Rio de Janerio 2011

Wilk N, Kloc K. To get the right price – A decision support method to optimize managerial decisions on public funding price to apply for. Value Health. 2011;14(7):A422

Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kötter I, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13(3):R75.

Zhang Q, Jameson K, Bolinder B, Angeletti F, Liczencziás E, Neumann M, et al. Annual Medical Expenditure and Mortality Related to Acute Coronary Syndrome (ACS) in the United Kingdom – A Systematic Review. Value Health. 2011;14(7):A375.

Berto P, Antonelli M, Ronco C, Cruz D, Melotti RM. Cost-effectiveness of polymyxin b immobilized fiber column and conventional medical therapy in the management of severe abdominal sepsis in Italy. Blood Purif 2011;32:331-340

Themistoclakis S, Tritto M, Bertaglia E, Berto P, Bongiorni MG, Catanzariti D, De Fabrizio G, De Ponti R, Grimaldi M, Pandozi C, Tondo C, Gulizia M. Catheter ablation of atrial fibrillation: Health Technology Assessment Report from the Italian Association of Arrhythmology and Cardiac Pacing (AIAC). G Ital Cardiol (Rome). 2011 Nov;12(11):726-76. Italian.

Berto P, Amato MP, Bellantonio P, Bortolon F, Cavalla P, Florio C, Lugaresi A, Montanari E, Rottoli MR, Simone IL, Zaffaroni M. The Direct Cost of Patients with Multiple Sclerosis: a Survey from Italian MS Centers. Neurol Sci 32:1035-1041, 2011

Berto P, Lopatriello S. Italy – Medical Devices & Diagnostics. In: ISPOR Global Health Care Systems Road Map http://www.ispor.org/htaroadmaps/Italy/Italy_MDD.asp Sept 2011

Mattar L, Godart N, Melchior JC, Falissard B, Kolta S, Ringuenet D, Vindreau C, Nordon C, Blanchet C, Pichard C.Underweight patients with anorexia nervosa: comparison of bioelectrical impedance analysis using five equations to dual X-ray absorptiometry. Clin Nutr. 2011 Dec; 30(6):746-52.

Parker DR, Luo X, Jalbert JJ, Assaf AR. Impact of upper and lower gastrointestinal blood loss on healthcare utilization and costs: a systematic review. J Med Econ. 2011; 14(3):279-87.

Jalbert JJ, Daiello LA, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of diabetes in nursing home residents with dementia. Am J Geriatr Pharmacother. 2011 Jun; 9(3):153-63.

Dab W, Rossignol M, Luce D, Benichou J, Marconi A, Clement P, Aubier M, Zmirou-Navier D, Abenhaim L. Cancer mortality study among French cement production workers. Int Arch Occup Environ Health. 2011 Feb; 84(2):167-73.

Autret-Leca E, Kreft-Jais C, Elefant E, Cissoko H, Darrouzain F, Grimaldi-Bensouda L, Attia S, Jonville-Bera AP.Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France. Drug Saf. 2010 Aug 1; 33(8):659-65.
Beau-Salinas F, Jonville-Bera AP, Cissoko H, Bensouda-Grimaldi L, Autret-Leca E.Drug dependence associated with triptans and ergot derivatives: a case/non-case study. Eur J Clin Pharmacol. 2010 Apr; 66(4):413-7.

Brandi C, Grimaldi L, Nisi G, Brafa A, Campa A, CalabroM, Campana M, D’Aniello C.The role of carbon dioxide therapy in the treatment of chronic wounds. In Vivo. 2010 Mar-Apr; 24(2):223-6.

Grimaldi-Bensouda L, Abenhaim L, Michaud L, Mouterde O, Jonville-Bera AP, Giraudeau B, David B, Autret-Leca E.Clinical features and risk factors for upper gastrointestinal bleeding in children: a case-crossover study. Eur J Clin Pharmacol. 2010 Aug; 66(8):831-7.

Grimaldi-Bensouda L, Marty M, Pollak M, Cameron D, Riddle M, Charbonnel B, Barnett AH, Boffetta P, Boivin JF, Evans M, Rossignol M, Benichou J, Abenhaim L.The international study of insulin and cancer. Lancet. 2010 Sep 4; 376(9743):769-70.

Grimaldi-Bensouda L, Rossignol M, Aubrun E, El Kerri N, Benichou J, Abenhaim L.Agreement between patients’ self-report and physicians’ prescriptions on cardiovascular drug exposure: the PGRx database experience. Pharmacoepidemiol Drug Saf. 2010 Jun; 19(6):591-5.

Goetghebeur M, Wagner M, Khoury H, Rindress D, Gregoire J-P, Deal C. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients. Cost Eff Resour Alloc 2010;8(1):4

Kekow J, Moots R, Emery P, Durez.P., Koenig.A., Singh A, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial. Ann Rheum Dis 2010;69(1):222-5.

Ogilvie I, Newton N, Welner S, Cowell W, Lip G. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010;123(7):638-45.

Berenson K, Casciano R, Makenbaeva D, Mozaffari E, Lamerato L, Corbelli J. Economic consequences of severe bleeding in patients with acute coronary syndrome in the USA. Adv Ther. 2010;27(8):564-79.

Arenas MD, Rebollo P, Malek T, Moledous A, Gil MT, Alvarez-Ude F, et al. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol. 2010;23(6):683-92.

Espuna-Pons M, Blasco P, Perez M, Rebollo P. Nocturia in patients with overactive bladder. Arch Esp Urol. 2010;63(5):363-72.

Martinez-Agullo E, Ruiz Cerda JL, Arlandis GS, Rebollo P, Perez M, Chaves J. [Analysis of overactive bladder and urinary incontinence in males in the age range between 50 and 65 years. EPICC study]. Actas Urol Esp. 2010;34(6):543-8.

Martinez-Agullo E, Ruiz-Cerda JL, Arlandis S, Rebollo P, Perez M, Chaves J. [Analysis of overactive bladder and urinary incontinence in working women aged between 25 and 64 years. EPICC study]. Actas Urol Esp. 2010;34(7):618-24.

Martinez Agullo E, Ruiz Cerda JL, Gomez PL, Rebollo P, Perez M, Chaves J. [Impact of urinary incontinence and overactive bladder syndrome on health-related quality of life of working middle-aged patients and institutionalized elderly patients]. Actas Urol Esp. 2010;34(3):242-50.

Rebollo P, Cuervo J, Villa G, Barreda MJ, Tranche S, Sanchez-Baragano MA, et al. [Development and validation of a generic questionnaire for evaluating satisfaction in patients with chronic disease: the SAT-Q Questionnaire]. Aten Primaria. 2010;42(12):612-9.

Rebollo P, Castejon I, Cuervo J, Villa G, Garcia-Cueto E, Diaz-Cuervo H, et al. Validation of a computer-adaptive test to evaluate generic health-related quality of life. Health Qual Life Outcomes. 2010;8:147.

Kujawska A, Nogas G. Transparency of drug reimbursement in Poland-oncology. Value Health. 2010;13(7):A278

Nogas G, Walczak J, Malczak I, Garbacka M, Obrzut G, Pieniazek I. Economic analysis of escitalopram (generic drug) in major depressive disorder (MDD). Value Health. 2010;13(3):A114

Walczak J, Augustynska J, Soltys E, Nogas G. Budget impact analysis of sertindole in the treatment of schizophrenia in Poland. Value Health. 2010;13(7):A446-A447

Walczak J, Małysiak S, Rowinska M. Comparative analysis of the efficacy and safety of escitalopram with sertraline and venlafaxine in the treatment of major depressive disorder (MDD). Value Health. 2010;13(3):A107

Walczak J, Stelmachowski J, Obrzut G, Nogas G. Cost-utility analysis (CUA) of sertindole in the treatment of schizophrenia in Poland in general population of schizophrenic patients and population of patients intolerant to at least one other antipsychotic agent: A five-year markov model. Value Health. 2010;13(7):A453

Walczak J, Nogas G, Garbacka M, Pieniazek I, Lis J, Obrzut G. Economic analysis of enoxaparin in comparison with fondaparinux in the treatment of deep-vein thrombosis (DVT). Value Health. 2010;13(3):A164

Walczak J, Nogas G, Garbacka M, Obrzut G, Pieniazek I. Escitalopram (generic drug) in major depressive disorder (MDD) – Budget impact analysis. Value Health. 2010;13(3):A109

Walczak J, Kaleta A, Gabrys E, Kloc K, Thangaratinam S, Barnfield G, et al. How are “teaching the teachers” courses in evidence based medicine evaluated? A systematic review. BMC Med Educ. 2010;10:64.

Walczak J. Systematic review of methods for meta-analysis and indirect comparison used in existing systematic reviews and hta reports-results from the first part of ebayesmet project. Value Health. 2010;13(7):A39

Walczak J, Nikodem M, Siedmiogrodzki K, Zapalska A, Borowiack E. Systematic review of statistical methods of meta-analysis and indirect comparison potentially available to use in systematic reviews-Results from the first part of ebayesmet project. Value Health. 2010;13(7):A339-A340

Wilk NM. A proposal of classification of public funding restrictions. Value Health. 2010;13(7):A419-A420

Blumberg EA, Hauser IA, Stanisic S, Mueller E, Berenson K, Gahlemann CG, et al. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation. 2010;90(12):1420-6.

Lewis G, Peake M, Aultman R, Gyldmark M, Morlotti L, Creeden J, et al. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res. 2010;38(1):9-21.

Mueller E. Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). Lung Cancer. 2010;69 Suppl 1:S1-S3.

Stanisic S, Bischoff HG, Heigener DF, Vergnenegre A, de Castro Carpeño J, Chouaid C, et al. Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC). Lung Cancer. 2010;69 Suppl 1:S24-S30.

Incorvaia C, Masieri S, Berto P, Scurati S, Frati F. Specific immunotherapy by the sublingual route for respiratory allergy. Allergy, Asthma & Clinical Immunology2010 Nov 9;6(1):29..

Berto P, Inzitari D, Scrutinio D, Cimminiello C, Lopatriello S, Rudelli G, Didoni G. Clopidogrel Idrogenosolfato versus Aspirina nella Riduzione degli Eventi Aterotrombotici nelle popolazioni ad elevato rischio cardiovascolare: un’analisi italiana di costo-efficacia basata sul trial CAPRIE. PharmacoEconomics – Italian Research Articles 2010; 12 (1): 1-18

Berto P, Maggi S, Noale M, Lopatriello S. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. Aging Clin Exp Res. 2010; 22 (2):179-188

Cozzi F, Tiso F, Lopatriello S, Ciprian L, Sfriso P, Berto P, Punzia L, The social costs of digital ulcer management in scleroderma patients: An observational Italian pilot study. Joint Bone Spine 2010 Jan;77(1):83-4

Dixon A, Khachatryan A.A review of the public health impact of the Quality and Outcomes Framework. Qual Prim Care. 2010; 18(2):133-8.

Jalbert JJ, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc. 2010 Feb; 11(2):120-7.